论文部分内容阅读
对休克综合征和弥漫性血管内凝血(DIC)的恰当治疗是血液学中需要迫切解决的问题。最理想的治疗是抑制发病时涉及的接触蛋白酶和制止随后的消耗性凝血过程。对后者,正在设计生产一种适当的重组药物。本文讨论了应用生物工程制备的丝氨酸蛋白酶类抑制剂。
Proper treatment of shock syndrome and diffuse intravascular coagulation (DIC) is a problem that needs urgent solution in hematology. The ideal treatment is to inhibit the onset of exposure to proteases involved and to stop the subsequent consumptive coagulation process. For the latter, a suitable recombinant drug is being designed and manufactured. This article discusses the use of bioengineered serine protease inhibitors.